- Home
- ATAI vs RCS Comparison
ATAI vs RCS Comparison
Compare ATAI & RCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATAI
- RCS
- Stock Information
- Founded
- ATAI 2018
- RCS 1994
- Country
- ATAI Germany
- RCS United States
- Employees
- ATAI N/A
- RCS N/A
- Industry
- ATAI Biotechnology: Pharmaceutical Preparations
- RCS Investment Managers
- Sector
- ATAI Health Care
- RCS Finance
- Exchange
- ATAI Nasdaq
- RCS Nasdaq
- Market Cap
- ATAI 280.2M
- RCS 292.8M
- IPO Year
- ATAI 2021
- RCS N/A
- Fundamental
- Price
- ATAI $1.48
- RCS $6.22
- Analyst Decision
- ATAI Strong Buy
- RCS
- Analyst Count
- ATAI 4
- RCS 0
- Target Price
- ATAI $9.00
- RCS N/A
- AVG Volume (30 Days)
- ATAI 2.9M
- RCS 141.1K
- Earning Date
- ATAI 03-27-2025
- RCS 01-01-0001
- Dividend Yield
- ATAI N/A
- RCS 10.12%
- EPS Growth
- ATAI N/A
- RCS N/A
- EPS
- ATAI N/A
- RCS N/A
- Revenue
- ATAI $331,000.00
- RCS N/A
- Revenue This Year
- ATAI $80.07
- RCS N/A
- Revenue Next Year
- ATAI N/A
- RCS N/A
- P/E Ratio
- ATAI N/A
- RCS N/A
- Revenue Growth
- ATAI N/A
- RCS N/A
- 52 Week Low
- ATAI $0.78
- RCS $4.51
- 52 Week High
- ATAI $2.85
- RCS $6.31
- Technical
- Relative Strength Index (RSI)
- ATAI 41.75
- RCS 41.83
- Support Level
- ATAI $1.37
- RCS $6.21
- Resistance Level
- ATAI $1.50
- RCS $6.40
- Average True Range (ATR)
- ATAI 0.14
- RCS 0.14
- MACD
- ATAI -0.04
- RCS 0.01
- Stochastic Oscillator
- ATAI 29.73
- RCS 27.71
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.
About RCS PIMCO Strategic Income Fund Inc.
PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with this objective.